Quantcast
Channel: WN.com - Articles related to Actelion to enter Phase II clinical development with new dual orexin receptor antagonist in patients with insomnia (Actelion Ltd)
Viewing all articles
Browse latest Browse all 480

ACTELION STATEMENT (Actelion Ltd)

$
0
0
(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 10 September 2015- Actelion Ltd (SIX: ATLN) confirmed today that it has initiated preliminary discussions with ZS Pharma, Inc. (ZSPH) without any commitment on either party. Actelion does not intend to make any further comments at this time. ### NOTES TO THE EDITOR ACTELION LTD Actelion Ltd. is a leading biopharmaceutical company focused on the discovery, development and commercialization of innovative drugs for diseases with significant unmet medical needs. Actelion is a leader in the field...

Viewing all articles
Browse latest Browse all 480

Trending Articles



<script src="https://jsc.adskeeper.com/r/s/rssing.com.1596347.js" async> </script>